Corvus Pharmaceuticals (CRVS) posts 2026 annual shareholder meeting voting outcomes

Rhea-AI Filing Summary

Corvus Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders, where stockholders voted on director elections, auditor ratification, and executive compensation.

Two Class I directors, Richard A. Miller, M.D., and Linda S. Grais, M.D., J.D., were elected to serve until the 2029 annual meeting. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, on a non-binding advisory basis, stockholders approved the compensation of the company’s named executive officers. A total of 73,021,854 shares of common stock were voted out of 84,090,424 shares outstanding as of the April 16, 2026 record date.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares outstanding: 84,090,424 shares Shares voted: 73,021,854 shares Votes for Miller: 58,275,179 votes +3 more

6 metrics

Shares outstanding 84,090,424 shares Common stock entitled to vote as of April 16, 2026

Shares voted 73,021,854 shares Common stock voted at 2026 Annual Meeting

Votes for Miller 58,275,179 votes Election of Richard A. Miller, M.D., Class I director

Votes for Grais 53,185,380 votes Election of Linda S. Grais, M.D., J.D., Class I director

Auditor ratification for votes 72,864,335 votes For ratification of PricewaterhouseCoopers LLP for FY ending Dec 31, 2026

Executive pay votes for 58,936,532 votes For non-binding advisory approval of named executive officer compensation

Key Terms

record date, broker non-votes, independent registered public accounting firm, non-binding advisory vote, +1 more

5 terms

record date financial

"Only stockholders of record at the close of business on April 16, 2026, the record date for the Annual Meeting"

The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.

broker non-votes financial

"Richard A. Miller, M.D. ... 12,049,623 Broker Non - Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm financial

"ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

non-binding advisory vote financial

"Proposal No. 3 —Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers"

A non-binding advisory vote is a shareholder vote that expresses investors’ opinion on a proposal (such as executive pay, corporate policy, or governance practices) but does not legally force the company to act. Think of it like a customer survey: it signals whether owners approve or disapprove and can pressure boards and managers to change course, so investors watch the result as an indicator of governance risk and potential future shifts in company strategy or leadership.

named executive officers financial

"the Company’s stockholders approved the compensation of the Company’s named executive officers"

Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

false 0001626971 0001626971 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2026

CORVUS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-37719		46-4670809
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

901 Gateway Boulevard, Third Floor South San Francisco, CA	94080
(Address of principal executive offices)	(Zip code)

Registrant’s telephone number, including area code: (650) 900-4520

Former name or former address, if changed since last report: Not applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, Par Value $0.0001 per share	CRVS	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 11, 2026, Corvus Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Only stockholders of record at the close of business on April 16, 2026, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, there were 84,090,424 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 73,021,854 shares of the Company’s common stock were voted in person or by proxy for the three proposals set forth below, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.

The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

Proposal No. 1 — Election of Directors

The Company’s stockholders elected the Class I director nominees below to the Company’s Board of Directors to hold office until the 2029 Annual Meeting of Stockholders or until his or her respective successor is elected and qualified or appointed, or the earlier of his or her death, resignation or removal. 

Class III Director Nominees		Votes For		Votes Withheld		Broker Non-Votes
Richard A. Miller, M.D.		58,275,179		2,697,052		12,049,623
Linda S. Grais, M.D., J.D.		53,185,380		7,786,851		12,049,623

Proposal No. 2 — Ratification of Selection of Independent Registered Accounting Firm

The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.

Votes For		Votes Against		Abstain
72,864,335		105,674		51,845

Proposal No. 3 —Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers

On a non-binding advisory basis, the Company’s stockholders approved the compensation of the Company’s named executive officers.

Votes For		Votes Against		Abstain		Broker Non-Votes
58,936,532		1,971,370		64,329		12,049,623

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CORVUS PHARMACEUTICALS, INC.
Date: June 12, 2026	By:	/s/ Leiv Lea
		Leiv Lea
		Chief Financial Officer

FAQ

What did Corvus Pharmaceuticals (CRVS) report in its latest stockholder meeting filing?

Corvus Pharmaceuticals reported the voting results of its 2026 Annual Meeting of Stockholders. Investors can see how shares were voted on director elections, auditor ratification, and executive compensation, including detailed vote counts for each proposal and overall meeting participation levels.

How many Corvus Pharmaceuticals (CRVS) shares were eligible and voted at the 2026 Annual Meeting?

There were 84,090,424 CRVS common shares outstanding and entitled to vote as of April 16, 2026. At the meeting, 73,021,854 shares were voted in person or by proxy, showing high participation in the governance decisions presented.

Which directors were elected at Corvus Pharmaceuticals’ (CRVS) 2026 Annual Meeting?

Stockholders elected Richard A. Miller, M.D. and Linda S. Grais, M.D., J.D. as Class I directors. They will serve until the 2029 Annual Meeting of Stockholders, or until a successor is elected and qualified or earlier death, resignation, or removal.

Did Corvus Pharmaceuticals (CRVS) stockholders ratify the company’s independent auditor for 2026?

Yes. Stockholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 72,864,335 votes for, 105,674 votes against, and 51,845 abstentions recorded.

How did Corvus Pharmaceuticals (CRVS) stockholders vote on executive compensation in 2026?

On a non-binding advisory basis, stockholders approved compensation for Corvus Pharmaceuticals’ named executive officers. The vote totaled 58,936,532 shares for, 1,971,370 against, 64,329 abstentions, and 12,049,623 broker non-votes recorded on this pay-related proposal.

What was the outcome of Proposal No. 1 at the Corvus Pharmaceuticals (CRVS) 2026 Annual Meeting?

Proposal No. 1, the election of Class I directors, passed. Richard A. Miller, M.D., received 58,275,179 votes for and 2,697,052 withheld, while Linda S. Grais, M.D., J.D., received 53,185,380 votes for and 7,786,851 withheld, plus 12,049,623 broker non-votes each.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB